Pulmonary Fibrosis Treatment Market Analysis

The market is segmented by drug and by region, out of which, the drug segment is further bifurcated into pirfenidone and nintedanib. The segment for pirfenidone is anticipated to hold the largest share in the pulmonary fibrosis treatment market on account of increased usage of the drug ever since it received approval by the Food and Drug Administration (FDA). Esbriet is a pirfenidone drug manufactured by Genentech, Inc. and approved by the U.S. FDA in 2014 in the United States. The drug is available as oral dosage in the form of either capsules or tablets. The most common adverse reactions consist of rash, nausea, headache, fatigue, dizziness, insomnia and upper respiratory tract infections. The segment for nintedanib is predicted to grow at a substantial rate as well, owing to the high demand for the drug. Ofev is a nintedanib drug which received FDA approval in 2014 in the United States. This drug, developed by Boehringer Ingelheim International GmbH, is in the form of capsules for oral use. Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Our in-depth analysis of the global market includes the following segments